The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Myeloma
and
The Myeloma Guide: Information for Patients and Caregivers
- In July 2025, the Food and Drug Administration (FDA) approved the use of linvoseltamab-gcpt (Lynozyfic™) for the treatment of relapsed or refractory adult patients with multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.